Saltar al contenido
Merck
  • Binding of prorenin to (pro)renin receptor induces the proliferation of human umbilical artery smooth muscle cells via ROS generation and ERK1/2 activation.

Binding of prorenin to (pro)renin receptor induces the proliferation of human umbilical artery smooth muscle cells via ROS generation and ERK1/2 activation.

Journal of the renin-angiotensin-aldosterone system : JRAAS (2014-03-05)
Feng Y Liu, Xiao Y Liu, Li J Zhang, Yun P Cheng, Yi N Jiang
RESUMEN

Since the discovery of the (pro)renin receptor (PRR), it has been considered as a novel bioactive molecule of the renin-angiotensin system (RAS). The activation of PRR can elicit a series of angiotensin II (AngII)-independent effects. In this study, we investigated the effects of prorenin and PRR on the proliferation of human umbilical artery smooth muscle (HUASM) cells and explored the possible mechanisms underlying these effects. The binding of prorenin to PRR can promote proliferation and upregulate the anti-apoptotic protein Bcl-2 and downregulate the pro-apoptotic protein Bax independently of AngII in HUASM cells. In addition, the binding of prorenin to PRR can also increase the production of reactive oxygen species (ROS) and the phosphorylation of extracellular signal-regulated kinase (ERK1/2) independently of AngII. The pretreatment of HUASM cells with an NADPH oxidase inhibitor DPI decreased the production of ROS and also decreased the phosphorylation of ERK1/2. Furthermore, pretreatment of HUASM cells with DPI and the ERK1/2 inhibitor PD98059 significantly attenuated the prorenin-induced proliferation and regulation of apoptosis factors. Binding of prorenin to PRR can induce HUASM cell proliferation via the ROS generation and ERK1/2 activation.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Valsartan, ≥98% (HPLC)
Sigma-Aldrich
PD 98,059, solid
USP
Valsartan, United States Pharmacopeia (USP) Reference Standard
Valsartan, European Pharmacopoeia (EP) Reference Standard
Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard
Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
MISSION® esiRNA, targeting human NECTIN1
Sigma-Aldrich
MISSION® esiRNA, targeting human NR1I2
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Atp6ap2
Sigma-Aldrich
MISSION® esiRNA, targeting human ATP6AP2
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Pvrl1